Tryp Therapeutics Inc. (TRYPF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tryp Therapeutics Inc. (TRYPF) trades at $0.0562 with AI Score 44/100 (Grade C). Tryp Therapeutics Inc. is a pharmaceutical company focused on developing compounds for neuropsychiatric disorders with unmet medical needs, utilizing synthetic psilocybin-based therapies. Market cap: $5.42M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for TRYPF: TRYPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TRYPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TRYPF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Tryp Therapeutics Inc. (TRYPF) Healthcare & Pipeline Overview
Tryp Therapeutics Inc. is a biotechnology firm specializing in the development of psilocybin-based therapeutics for neuropsychiatric disorders, including fibromyalgia and binge eating disorder. Their focus on unmet medical needs and strategic partnerships places them within the evolving landscape of psychedelic medicine.
What Is the Investment Thesis for TRYPF?
Tryp Therapeutics presents a high-risk, high-reward investment opportunity within the burgeoning psychedelic medicine sector. The company's focus on synthetic psilocybin-based therapies for neuropsychiatric disorders addresses a significant unmet medical need. Key value drivers include the successful advancement of TRP-8802 and TRP-8803 through clinical trials, positive clinical data readouts, and potential regulatory approvals. The company's partnerships with Calvert Labs and Fluence are also crucial for de-risking the development process. However, investors should be aware of the inherent risks associated with early-stage pharmaceutical development, including clinical trial failures, regulatory hurdles, and funding challenges. The company's market capitalization of $5.42M reflects its early stage and speculative nature.
Based on FMP financials and quantitative analysis
TRYPF Key Highlights
Market capitalization of $5.42M indicates the company's early stage and speculative nature.
- Focus on synthetic psilocybin-based therapies positions the company in the emerging psychedelic medicine market.
- Lead program, (PFN), targets neuropsychiatric disorders with high unmet medical needs, including fibromyalgia and binge eating disorder.
- Partnerships with Calvert Labs and Fluence provide expertise in study design and psychotherapeutic support for clinical trials.
- P/E ratio of -1.10 reflects the company's current lack of profitability, typical for early-stage biotech companies.
Who Are TRYPF's Competitors?
TRYPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
| DTXMF Deltex Medical Group plc | $0.10 | +0.00% | $181M | 51 |
| FFLWF Fire & Flower Holdings Corp. | $0.12 | -44.37% | $5.42M | 41 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRYPF's Key Strengths?
Proprietary PFN program targeting unmet medical needs.
- Focus on synthetic psilocybin, potentially offering advantages over natural sources.
- Strategic partnerships with Calvert Labs and Fluence.
- Experienced management team with expertise in drug development.
What Are TRYPF's Weaknesses?
Early-stage company with limited financial resources.
- High dependence on the success of its PFN program.
- Limited clinical data and regulatory approvals to date.
- OTC market listing may limit access to capital.
What Could Drive TRYPF Stock Higher?
Clinical trial data readouts for TRP-8802 in fibromyalgia.
- Clinical trial data readouts for TRP-8803 in binge eating disorder.
- Potential regulatory submissions for TRP-8802 or TRP-8803.
- Progress in expanding the PFN program to other neuropsychiatric disorders.
- Strategic partnerships and collaborations to accelerate development.
What Are the Key Risks for TRYPF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory hurdles.
- Competition from other companies developing psychedelic therapies.
- Changing regulatory landscape and public perception of psychedelics.
- Funding challenges and dilution of existing shareholders.
- Limited liquidity and price volatility due to OTC market listing.
What Are the Growth Opportunities for TRYPF?
- Advancement of TRP-8802 for Fibromyalgia: Fibromyalgia affects millions worldwide, creating a substantial market opportunity. Successful clinical trials and regulatory approval for TRP-8802 could establish Tryp as a leader in fibromyalgia treatment. The timeline for potential market entry depends on clinical trial progress and regulatory review, but could be within 3-5 years, capturing a portion of the multi-billion dollar pain management market.
- Development of TRP-8803 for Binge Eating Disorder: Binge eating disorder represents another significant unmet medical need. Positive clinical data for TRP-8803 could lead to regulatory approval and commercialization, addressing a market with limited effective treatments. The timeline for potential market entry is contingent on clinical trial outcomes and regulatory approval, potentially within 4-6 years, tapping into the growing market for eating disorder treatments.
- Expansion of PFN Program to Other Neuropsychiatric Disorders: Tryp's PFN program has the potential to be expanded to treat other neuropsychiatric disorders beyond the initial target indications. This could significantly broaden the company's market reach and revenue potential. The timeline for expansion depends on research and development efforts, but could lead to new clinical programs within 2-3 years, diversifying the company's pipeline.
- Strategic Partnerships and Collaborations: Forming additional strategic partnerships with research institutions, pharmaceutical companies, or patient advocacy groups could accelerate Tryp's development programs and expand its market access. These partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. New partnerships could be established within the next 1-2 years, providing immediate benefits to the company's operations.
- Intellectual Property Protection: Securing strong intellectual property protection for its PFN program and related technologies is crucial for maintaining a competitive advantage. Patents and other forms of IP protection can prevent competitors from developing similar products and therapies, ensuring Tryp's long-term market position. Ongoing efforts to strengthen IP protection will be essential in the coming years, safeguarding the company's innovations.
What Are TRYPF's Competitive Advantages?
- Proprietary PFN (Psilocybin-For-Neuropsychiatric) program.
- Focus on synthetic psilocybin, potentially offering advantages over natural psilocybin.
- Strategic partnerships with Calvert Labs and Fluence.
- Intellectual property protection for their drug candidates and technologies.
What Does TRYPF Do?
Tryp Therapeutics Inc., formerly Artos Pharma Corp., was founded in 2019 and is based in Kelowna, Canada. The company is dedicated to identifying and developing innovative pharmaceutical compounds for diseases characterized by significant unmet medical needs. Tryp's primary focus lies in the development of its proprietary PFN (Psilocybin-For-Neuropsychiatric) program. This program utilizes formulations of synthetic psilocybin to treat a range of neuropsychiatric disorders. The company's lead product candidates within the PFN program include TRP-8802 and TRP-8803. These candidates are being developed for various indications, including fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. Tryp Therapeutics has established strategic partnerships to advance its research and development efforts. The company has an agreement with Calvert Labs to design and execute exploratory studies related to its psilocybin-for-neuropsychiatric disorders program. Additionally, Tryp has a service agreement with Fluence to provide design and training for the psychotherapeutic portion of its clinical trial activities. These collaborations are crucial for the comprehensive development and clinical application of Tryp's therapeutic programs. Tryp is positioning itself to be a key player in the emerging field of psychedelic medicine.
What Products and Services Does TRYPF Offer?
- Develop synthetic psilocybin-based therapies for neuropsychiatric disorders.
- Focus on diseases with high unmet medical needs, such as fibromyalgia and binge eating disorder.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Partner with research institutions and other companies to advance their development programs.
- Seek regulatory approval for their therapies from health authorities like the FDA.
- Commercialize their approved therapies to treat patients in need.
How Does TRYPF Make Money?
- Develop proprietary pharmaceutical compounds for neuropsychiatric disorders.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through product sales, licensing fees, and milestone payments.
- Focus on intellectual property protection to maintain market exclusivity.
What Industry Does TRYPF Operate In?
Tryp Therapeutics operates within the rapidly evolving biotechnology industry, specifically targeting the emerging field of psychedelic medicine. The market for psychedelic-assisted therapies is projected to experience substantial growth, driven by increasing acceptance of psychedelics for treating mental health disorders and neurological conditions. This market is characterized by intense competition among companies developing novel psychedelic compounds and therapies. Key competitors include firms developing similar psilocybin-based treatments, as well as those focused on other psychedelic substances like MDMA and ketamine. Regulatory pathways and evolving legal frameworks will significantly impact the growth and commercialization of psychedelic medicines.
Who Are TRYPF's Key Customers?
- Patients suffering from neuropsychiatric disorders, such as fibromyalgia and binge eating disorder.
- Physicians who prescribe medications for these conditions.
- Hospitals and clinics that provide treatment for neuropsychiatric disorders.
- Pharmaceutical companies that may license or acquire Tryp's therapies.
How Tryp Therapeutics Inc. Is Valued
Tryp Therapeutics Inc. carries a market capitalization of $5.42M, placing it in the micro-cap category. Relative to its peer group, TRYPF's quantitative score of 44/100 is below the peer average of 58/100.
Company Profile
Tryp Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kelowna, CA. The company is led by CEO Jason Carroll. TRYPF has traded publicly since 2021.
Key Financial Metrics
Return on equity for Tryp Therapeutics Inc. stands at 402.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -62.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.24 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -91.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Tryp Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TRYPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its potential for growth.
- Community sentiment has turned increasingly positive, with discussions highlighting the innovative nature of Tryp's therapeutic approaches.
- Recent announcements of partnerships and collaborations may enhance Tryp's credibility and market reach, fostering optimism among investors.
- The growing interest in psychedelic therapies aligns with broader market trends, positioning Tryp favorably within an expanding sector.
Bear Case
- Concerns over regulatory hurdles in the psychedelic space might create uncertainty, leading some investors to adopt a cautious stance.
- Recent volatility in community sentiment reflects mixed opinions, with some traders expressing skepticism about the company's ability to deliver on its promises.
- Market perception remains wary due to the speculative nature of the industry, which can deter conservative investors from committing capital.
- Insufficient financial performance metrics in recent reports may raise red flags for potential investors, leading to hesitance in market participation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TRYPF Latest News
No recent news available for TRYPF.
TRYPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRYPF.
Price Targets
Wall Street price target analysis for TRYPF.
TRYPF MoonshotScore
What does this score mean?
The MoonshotScore rates TRYPF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jason Carroll
CEO
Jason Carroll is the CEO of Tryp Therapeutics. Information regarding his detailed background, career history, education, and previous roles is not available in the provided data. Further research would be needed to provide a comprehensive biography.
Track Record: Information regarding Jason Carroll's specific achievements, strategic decisions, and company milestones under his leadership at Tryp Therapeutics is not available in the provided data. Further research is needed to assess his track record.
TRYPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tryp Therapeutics may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history, distressed financials, or those that choose not to meet the requirements of higher tiers.
- OTC Tier: OTC Other
- Limited financial disclosure and regulatory oversight.
- Lower liquidity and wider bid-ask spreads.
- Increased risk of fraud or manipulation.
- Greater price volatility.
- Potential difficulty in obtaining accurate and reliable information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Monitor the company's news releases and public disclosures.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Focus on developing therapies for neuropsychiatric disorders with unmet medical needs.
- Partnerships with Calvert Labs and Fluence.
- Development of a proprietary PFN program.
- Scientific advisory board or key opinion leaders involved in the company's research.
- Company was incorporated in 2019.
Tryp Therapeutics Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for TRYPF?
TRYPF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Tryp Therapeutics Inc. is a pharmaceutical company focused on developing compounds for neuropsychiatric disorders with unmet medical needs, utilizing synthetic psilocybin-based therapies. Their …
What does Tryp Therapeutics Inc. do?
Tryp Therapeutics Inc. is a pharmaceutical company focused on developing innovative therapies for neuropsychiatric disorders with high unmet medical needs. Their primary focus is on their PFN (Psilocybin-For-Neuropsychiatric) program, which utilizes formulations of synthetic psilocybin. The company is developing TRP-8802 and TRP-8803 for conditions like fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity.
What do analysts say about TRYPF stock?
Analyst coverage of TRYPF is currently limited, reflecting its early stage and OTC market listing. Key valuation metrics are difficult to assess due to the company's lack of revenue and profitability. Growth considerations center around the successful advancement of its PFN program through clinical trials and regulatory approvals. Investors should conduct thorough due diligence and consider the inherent risks associated with early-stage biotech companies before investing in TRYPF.
What are the main risks for TRYPF?
The main risks for TRYPF include the inherent uncertainties of pharmaceutical development, such as clinical trial failures and regulatory hurdles. Competition from other companies developing psychedelic therapies also poses a risk. Furthermore, the changing regulatory landscape and public perception of psychedelics could impact the company's prospects. Funding challenges and the potential for dilution of existing shareholders are also significant risks, particularly given the company's early stage and OTC market listing.
What are the key factors to evaluate for TRYPF?
Tryp Therapeutics Inc. (TRYPF) holds an AI score of 44/100 (low). Tryp Therapeutics presents a high-risk, high-reward investment opportunity within the burgeoning psychedelic medicine sector. Not financial advice.
How frequently does TRYPF data refresh on this page?
TRYPF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TRYPF's recent stock price performance?
Tryp Therapeutics Inc. (TRYPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary PFN program targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRYPF overvalued or undervalued right now?
Tryp Therapeutics Inc. (TRYPF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TRYPF before investing?
Before investing in Tryp Therapeutics Inc. (TRYPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited source data.
- OTC market data may be less reliable than major exchange data.
- AI analysis pending for TRYPF.